There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Masimo (MASI – Research Report), Lyra Therapeutics (LYRA – Research Report) and Bausch + Lomb Corporation (BLCO – Research Report) with bullish sentiments.
Masimo (MASI)
In a report released yesterday, Marie Thibault from BTIG reiterated a Buy rating on Masimo, with a price target of $145.00. The company’s shares closed last Friday at $134.93.
According to TipRanks.com, Thibault is a 1-star analyst with an average return of -1.2% and a 35.3% success rate. Thibault covers the Healthcare sector, focusing on stocks such as Establishment Labs Holdings, Edwards Lifesciences, and Irhythm Technologies.
Masimo has an analyst consensus of Moderate Buy, with a price target consensus of $128.33.
See today’s best-performing stocks on TipRanks >>
Lyra Therapeutics (LYRA)
BTIG analyst Justin Zelin reiterated a Buy rating on Lyra Therapeutics yesterday and set a price target of $15.00. The company’s shares closed last Friday at $6.24, close to its 52-week high of $6.71.
According to TipRanks.com, Zelin is a 5-star analyst with an average return of 26.3% and a 47.2% success rate. Zelin covers the Healthcare sector, focusing on stocks such as Syndax Pharmaceuticals, Viking Therapeutics, and Immunocore Holdings.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Lyra Therapeutics with a $13.50 average price target, which is a 101.2% upside from current levels. In a report released yesterday, H.C. Wainwright also reiterated a Buy rating on the stock with a $12.00 price target.
Bausch + Lomb Corporation (BLCO)
In a report released yesterday, Larry Biegelsen from Wells Fargo maintained a Buy rating on Bausch + Lomb Corporation, with a price target of $23.00. The company’s shares closed last Friday at $16.17.
According to TipRanks.com, Biegelsen is a 5-star analyst with an average return of 11.5% and a 61.4% success rate. Biegelsen covers the Healthcare sector, focusing on stocks such as Axonics Modulation Technologies, GE Healthcare Technologies Inc, and Inspire Medical Systems.
Bausch + Lomb Corporation has an analyst consensus of Moderate Buy, with a price target consensus of $19.43.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on MASI: